Microenvironment factors do not afford myeloma cell lines protection from simvastatin
Alla Osadchy(Meir Medical Center), Michael Lishner(Tel Aviv University), Judith Radnay(Tel Aviv University), Liat Drucker(Meir Medical Center), Hava Shapira(Meir Medical Center)
Cited by 12
Related Papers
High incidence of BRCA1–2 germline mutations, previous breast cancer and familial cancer history in Jewish patients with uterine serous papillary carcinoma
|European Journal of Surgical Oncology|2006|63
Overexpression of tetraspanins affects multiple myeloma cell survival and invasive potential
|The FASEB Journal|2007|56
Simvastatin has deleterious effects on human first trimester placental explants
|Human Reproduction|2005|51
Secretome of human bone marrow mesenchymal stem cells: an emerging player in lung cancer progression and mechanisms of translation initiation
|Tumor Biology|2015|48
BRCA1/2 Germline Mutations in Jewish Patients With Uterine Serous Carcinoma
|International Journal of Gynecological Cancer|2010|47